Malaysia
Search
Sign In
Change Password
Points
Sign Out
Multidisciplinary
Top Medical News
The use of inferior vena cava filters appears to effectively reduce the risk of pulmonary embolism (PE) and PE-related and all-cause deaths in patients with venous thromboembolism (VTE), reports a recent meta-analysis.
Following a diet with high pro-inflammatory potential is associated with an increased risk of developing dementia, suggest data from the HELIAD* study.
A short-term treatment regimen based on high-dose gatifloxacin appears to be effective against multidrug- or rifampicin-resistant tuberculosis (TB) but at the cost of increased severe adverse drug reactions, as shown in a study.
Extraocular muscle injection of botulinum toxin type A (BTXA) results in a high rate of successful motor alignment, which is similar to that achieved following eye muscle surgery for nonparalytic, nonrestrictive horizontal strabismus, reports a recent study.
Despite significant progress in controlling air pollution, it remains an urgent public health problem, according to a recent European study, which found that more than 300,000 deaths in the region could be attributed to air pollution in 2019.
An extremely dense breast prior to and after menopause may double the risk of breast cancer, according to a Korean cohort study.
Short-course nonmacrolide therapy in patients with acute exacerbations of chronic obstructive pulmonary disease (AECOPD) appears to have no significant effect on outcomes including mortality, progression to ventilation, readmission rate, or prevalence of adverse drug events, a study has shown.
Special Reports
At a Pfizer-sponsored Masterclass, four distinguished speakers shared their insights into the role of NOACs in the management of NVAF and VTE, with a focus on apixaban (Eliquis®, Pfizer). Furthermore, the speakers discussed a stepwise approach to guide treatment choice amid the COVID-19 pandemic.
Esflurbiprofen 40 mg transdermal patch
Upadacitinib 15 mg XR-FC tab
It has been estimated that diabetes – a chronic metabolic disorder resulting in hyperglycaemia – affects 422 million adults globally.1 In 2019, the disease caused 1.5 million deaths worldwide and the number of people with diabetes is expected to reach 642 million by 2040.
During the Guardians for Health Summit 2021 supported by Boehringer Ingelheim, several distinguished speakers shared their insights into the importance of type 2 diabetes (T2D) guideline adherence and patient empowerment, as well as the impact of clinical inertia on the burden of cardiorenal metabolic diseases.
Romosozumab 105 mg/1.17 mL soln for inj
Heart failure with preserved
ejection fraction (HFpEF) represents a significant unmet medical need. The
EMPEROR-Preserved trial aimed to assess the impact of empagliflozin on
cardiovascular outcomes in patients with HFpEF. On 27 August 2021, during the
hotline session of the 2021 ESC Virtual Congress, the main results of the
EMPEROR-Preserved trial were presented by Professor Stefan Anker, principal
investigator of the study, and heart failure specialist at Charité Berlin,
Germany.
Conference Reports
Increased serum iron or transferrin saturation levels in individuals with non-alcoholic fatty liver disease (NAFLD) may point to an increased risk of hepatocellular carcinoma (HCC), according to a study presented at The Liver Meeting Digital Experience™.
Switching to tenofovir alafenamide (TAF) from nucleos(t)ide analogue therapies was associated with improved virologic response and liver function in patients with chronic hepatitis B virus (HBV) infection, even in those with decompensated HBV cirrhosis, according to real-world studies presented at AASLD 2021.
The pan-PPAR* agonist lanifibranor further advances into the NASH** treatment field, as more data from the phase IIb NATIVE*** study presented at AASLD 2021 unveil further histologic and therapeutic benefits for patients with NASH.
Empagliflozin provides a significant clinical benefit within 90 days and shows no safety concerns in patients hospitalized for acute heart failure (HF), according to results of the EMPULSE trial reported at the American Heart Association (AHA) Scientific Sessions 2021.
The SGLT2i* canagliflozin significantly improves symptoms and quality of life (QoL) early on during treatment in people with heart failure (HF) due to either reduced or preserved ejection fraction (rEF or pEF), regardless of whether they have type 2 diabetes (T2D), according to the CHIEF-HF** study presented at AHA 2021.
Non-overweight patients with non-alcoholic fatty liver disease (NAFLD) have an elevated risk of all-cause mortality following liver transplant and are also more likely to be removed from the liver transplant waitlist compared with obese/overweight patients, according to a study presented at The Liver Meeting Digital Experience™.
Treatment with inclisiran consistently reduced low-density lipoprotein cholesterol (LDL-C) levels in patients with, or at high risk of, atherosclerotic cardiovascular disease (ASCVD), regardless of glycaemic status, based on a pooled analysis of the ORION-10* and ORION-11** studies presented at AHA 2021.
Multimedia
